Trials / Recruiting
RecruitingNCT05678270
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
A Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-192 | ICP-192 is a round, uncoated tablet, 5mg, orally. |
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2026-05-01
- Completion
- 2026-12-01
- First posted
- 2023-01-10
- Last updated
- 2024-02-07
Locations
44 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05678270. Inclusion in this directory is not an endorsement.